Coming out of a white-hot streak during the early years of the pandemic, Boston's life sciences market looks like a bucket of ice water has been dropped on it. After billions of dollars in venture capital funding fueled a flood of new biotech leasing and development in the sector, a slowdown was inevitable, but several industry experts told Bisnow they didn't expect one of this magnitude for the nation's most significant lab cluster. The slowdown has caused pain this year for companies from biotech startups to spec developers, but experts say the Boston market still has strong fundamentals and they are optimistic it will recover as funding begins to return. 
Signs of the changing market emerged last year, but the damage accelerated at the beginning of 2023 as interest rates rose, funding dried up and two of the largest bank collapses in history hurt financing efforts. This led the sector to quickly cut growth plans and look to give back space, and… Read the full story here. | 
